Development and external validation of a nomogram for individualized adjuvant imatinib duration for high‐risk gastrointestinal stromal tumors: A multicenter retrospective cohort study

INTRODUCTION: The main emphasis of the research about adjuvant imatinib for high‐risk gastrointestinal stromal tumors (GISTs) is prolonging the treatment duration and ignores the heterogeneous that 10‐year recurrence rates ranged from about 20%–100%. Thus, this study evaluated the effect of differen...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ruolin, Wu, Yingxin, Gong, Jin, Zhao, Rui, Li, Li, Wan, Qianyi, Lian, Nan, Shen, Xiaoding, Xia, Lin, Shen, Yuhou, Xiao, Haitao, Wu, Xiaoting, Chen, Yi, Cen, Ying, Xu, Xuewen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385591/
https://www.ncbi.nlm.nih.gov/pubmed/35297216
http://dx.doi.org/10.1002/cam4.4673

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385591/
https://www.ncbi.nlm.nih.gov/pubmed/35297216
http://dx.doi.org/10.1002/cam4.4673

Ejemplares similares